{"id":1246,"date":"2020-04-14T11:53:11","date_gmt":"2020-04-14T09:53:11","guid":{"rendered":"http:\/\/invivo.partners\/?p=1246"},"modified":"2020-05-26T16:46:38","modified_gmt":"2020-05-26T14:46:38","slug":"nova-empresa-de-biologia-sintetica-amb-seu-a-barcelona-capta-una-inversio-de-dos-milions-deuros","status":"publish","type":"post","link":"https:\/\/invivo.partners\/ca\/2020\/04\/14\/nova-empresa-de-biologia-sintetica-amb-seu-a-barcelona-capta-una-inversio-de-dos-milions-deuros\/","title":{"rendered":"Nova empresa de biologia sint\u00e8tica amb seu a Barcelona capta una inversi\u00f3 de dos milions d\u2019euros"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Luis Serrano i Maria Lluch, del Centre de Regulaci\u00f3 Gen\u00f2mica (CRG) a Barcelona, \u200b\u200bhan fundat <a rel=\"noreferrer noopener\" href=\"https:\/\/www.pulmobio.com\/\" target=\"_blank\"><strong>Pulmobiotics S.L.<\/strong><\/a>, una empresa precl\u00ednica que utilitza la biologia sint\u00e8tica per desenvolupar nous tractaments i vacunes per diversos tipus de malalties pulmonars. La companyia ha obtingut 2.000.000 d\u2019euros de capital inicial d\u2019una de les firmes biom\u00e8diques de capital risc l\u00edders a Espanya, <a rel=\"noreferrer noopener\" href=\"http:\/\/invivo.partners\/\" target=\"_blank\"><strong>Invivo Ventures<\/strong><\/a>, amb seu a Barcelona.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Les malalties pulmonars s\u00f3n una de les principals causes de mort a la UE, incloses la malaltia pulmonar obstructiva cr\u00f2nica, la pneum\u00f2nia o l\u2019asma. Al 2016, un de cada dotze ciutadans de la UE va morir a causa d\u2019una malaltia respirat\u00f2ria, \u00e9s a dir, al voltant de 422.000 persones. A Espanya, aquesta xifra augmenta a un de cada deu ciutadans, i un de cada vuit ingressos hospitalaris s\u00f3n a causa de malalties respirat\u00f2ries.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">La pneum\u00f2nia associada al ventilador (VAP per les seves sigles en angl\u00e8s) \u00e9s un tipus d\u2019infecci\u00f3 pulmonar que es desenvolupa en pacients hospitalitzats connectats a m\u00e0quines de ventilaci\u00f3 mec\u00e0nica. Hi ha al voltant de 400.000 casos de VAP cada any a Europa i als EUA. La VAP \u00e9s letal per entre el 3 i el 17% dels pacients afectats, i als EUA augmenta els costos d\u2019hospitalitzaci\u00f3 entre 25.000 i 40.000 d\u00f2lars per pacient.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Pulmobiotics desenvolupar\u00e0 tractaments nous per combatre malalties com la VAP, mitjan\u00e7ant el disseny de bacteris atenuats que administren agents terap\u00e8utics, una de les aplicacions m\u00e9s prometedores en el camp emergent de la biologia sint\u00e8tica. Els bacteris dissenyats poden transportar una quantitat precisa de mol\u00e8cules terap\u00e8utiques fins el teixit afectat, superant moltes de les limitacions dels tractaments que s\u2019utilitzen actualment. L\u2019objectiu de la companyia \u00e9s desenvolupar un producte que redueixi l\u2019\u00fas d\u2019antibi\u00f2tics per tractar la VAP i que estigui llest per provar en pacients a partir del 2023.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>El director del CRG, Luis Serrano, PhD, diu<\/strong>: \u201cAquest \u00e9s un gran exemple de com una idea que sonava boja fa 15 anys, com la de fer servir bacteris com a una \u2018p\u00edndola viva\u2019 per tractar malalties en humans, pot convertir-se en realitat. Mostra que fer ci\u00e8ncia d&#8217;excel\u00b7l\u00e8ncia impulsada per la curiositat pot generar noves oportunitats comercials i de salut\u201d.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>La directora cient\u00edfica, Maria Lluch, PhD, diu<\/strong>: \u201cLa pand\u00e8mia actual de COVID-19 mostra la import\u00e0ncia de trobar noves formes de tractar i de protegir-nos dels agents infecciosos. La inversi\u00f3 inicial de Invivo Ventures ens permetr\u00e0 portar la plataforma que vam desenvolupar al CRG a la seg\u00fcent etapa: descobrir i traslladar a la cl\u00ednica una nova gamma de bioterap\u00e8utics i vacunes vives. Un cop validada a la cl\u00ednica, creiem que la nostra plataforma t\u00e9 el potencial de portar r\u00e0pidament al mercat vacunes contra nous agents infecciosos i, per tant, pot ser de gran valor per a fer front a situacions similars futures\u00bb.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Llu\u00eds Pareras, MD, PhD, soci fundador d\u2019Invivo Ventures diu<\/strong>: \u201cFins i tot en les circumst\u00e0ncies actuals de la pand\u00e8mia de COVID-19, la ci\u00e8ncia no pot ni ha d\u2019aturar-se. Pulmobiotics est\u00e0 intentant resoldre un problema que lamentablement \u00e9s molt important avui dia, l&#8217;exist\u00e8ncia de malalties infeccioses que s\u00f3n molt dif\u00edcils de tractar. L\u2019enfocament de la biologia sint\u00e8tica de Luis Serrano i Maria Lluch i els seus resultats precl\u00ednics en la lluita contra els agents infecciosos resistents a m\u00faltiples f\u00e0rmacs s\u00f3n extraordinaris i ens han conven\u00e7ut per invertir-hi\u00bb.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Albert Ferrer CFA, soci fundador d\u2019Invivo Ventures, diu<\/strong>: \u201cInvivo t\u00e9 com a objectiu recolzar la transfer\u00e8ncia de tecnologia des dels centres de recerca espanyols i millorar el creixement i el desenvolupament de productes innovadors. La inversi\u00f3 en Pulmobiotics \u00e9s un clar exemple d\u2019aquesta visi\u00f3 i estem particularment satisfets que permeti la creaci\u00f3 d\u2019un nou negoci i la creaci\u00f3 de 5 nous llocs de treball en aquest dif\u00edcil entorn econ\u00f2mic\u201d.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Anabel Sanz, PhD, responsable de l&#8217;Oficina de Transfer\u00e8ncia de Tecnologia i Desenvolupament de Negoci a CRG, diu:<\/strong> \u00abPulmobiotics \u00e9s un bon exemple de l&#8217;impacte decisiu de la recerca que fa el CRG en la salut i en la prosperitat econ\u00f2mica. \u00c9s a m\u00e9s fruit de l&#8217;estrat\u00e8gia d&#8217;ICREA i CRG per donar suport a investigadors amb talent. Un equip s\u00f2lid de quatre joves cient\u00edfics i emprenedors formats al CRG s&#8217;unir\u00e0 a l&#8217;empresa. Nascuda aqu\u00ed a Barcelona, Pulmobiotics t\u00e9 com a objectiu crear un impacte global. Estem encantats de tenir a Invivo Ventures com a soci en aquest viatge, que impulsar\u00e0 una tecnologia desenvolupada al CRG a una posici\u00f3 de lideratge en l&#8217;\u00e0mbit de les bioter\u00e0pies i vacunes vives.\u201d<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Governan\u00e7a<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Inicialment, s\u2019espera que Pulmobiotics ocupi un espai de laboratori al Parc de Recerca Biom\u00e8dica de Barcelona (PRBB) i que col\u00b7labori amb una xarxa de socis i prove\u00efdors espanyols i internacionals per a desenvolupar els seus productes.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">La fundadora i ex-investigadora del CRG, Maria Lluch, ser\u00e0 la directora cient\u00edfica, amb el director del CRG, Luis Serrano, com a president de la Junta Cient\u00edfica Assessora. Luis Serrano aporta una gran experi\u00e8ncia cient\u00edfica empresarial, havent estat un dels fundadors cient\u00edfics d\u2019En Vivo Pharmaceuticals, Diverdrugs i Cellzome, una companyia de tecnologia prote\u00f2mica adquirida al 2012 per GSK per 99 milions de d\u00f2lars en efectiu.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Claudio Santos, PhD, ser\u00e0 el director general. Claudio t\u00e9 experi\u00e8ncia en la creaci\u00f3 i inversi\u00f3 en companyies de les ci\u00e8ncies de la vida (Sixth Element Capital, Regne Unit) i en el desenvolupament de negocis, tan en l\u2019\u00e0mbit acad\u00e8mic (Cancer Research Technology, Regne Unit) com en la ind\u00fastria (Bioncotech Therapeutics, Espanya). Ha passat els darrers 8 mesos treballant amb els fundadors i el CRG en la captaci\u00f3 de fons i la creaci\u00f3 de l\u2019empresa.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Llu\u00eds Pareras i Albert Ferrer, socis fundadors d\u2019Invivo Ventures, administrada per Invivo Capital Partners, formaran part de la Junta Directiva de Pulmobiotics amb Maria Lluch i Claudio Santos.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Luis Serrano i Maria Lluch, del Centre de Regulaci\u00f3 Gen\u00f2mica (CRG) a Barcelona, \u200b\u200bhan fundat Pulmobiotics S.L., una empresa precl\u00ednica que utilitza la biologia sint\u00e8tica per desenvolupar nous tractaments i vacunes per diversos tipus de malalties pulmonars. La companyia ha obtingut 2.000.000 d\u2019euros de capital inicial d\u2019una de les firmes biom\u00e8diques de capital risc l\u00edders<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[516],"tags":[532,547,542,536,528,541,540,534,550,546],"class_list":["post-1246","post","type-post","status-publish","format-standard","hentry","category-noticias-ca","tag-albert-ferrer-ca","tag-fondo-inversion","tag-inversion","tag-investment","tag-invivo-capital-ca","tag-invivo-ventures","tag-lluis-pareras","tag-luis-pareras-ca","tag-pulmobiotics","tag-venture-capital"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Nova empresa de biologia sint\u00e8tica amb seu a Barcelona capta una inversi\u00f3 de dos milions d\u2019euros - Invivo Partners<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/invivo.partners\/ca\/2020\/04\/14\/nova-empresa-de-biologia-sintetica-amb-seu-a-barcelona-capta-una-inversio-de-dos-milions-deuros\/\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nova empresa de biologia sint\u00e8tica amb seu a Barcelona capta una inversi\u00f3 de dos milions d\u2019euros - Invivo Partners\" \/>\n<meta property=\"og:description\" content=\"Luis Serrano i Maria Lluch, del Centre de Regulaci\u00f3 Gen\u00f2mica (CRG) a Barcelona, \u200b\u200bhan fundat Pulmobiotics S.L., una empresa precl\u00ednica que utilitza la biologia sint\u00e8tica per desenvolupar nous tractaments i vacunes per diversos tipus de malalties pulmonars. La companyia ha obtingut 2.000.000 d\u2019euros de capital inicial d\u2019una de les firmes biom\u00e8diques de capital risc l\u00edders\" \/>\n<meta property=\"og:url\" content=\"https:\/\/invivo.partners\/ca\/2020\/04\/14\/nova-empresa-de-biologia-sintetica-amb-seu-a-barcelona-capta-una-inversio-de-dos-milions-deuros\/\" \/>\n<meta property=\"og:site_name\" content=\"Invivo Partners\" \/>\n<meta property=\"article:published_time\" content=\"2020-04-14T09:53:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-05-26T14:46:38+00:00\" \/>\n<meta name=\"author\" content=\"invivo\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrit per\" \/>\n\t<meta name=\"twitter:data1\" content=\"invivo\" \/>\n\t<meta name=\"twitter:label2\" content=\"Temps estimat de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minuts\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/invivo.partners\/ca\/2020\/04\/14\/nova-empresa-de-biologia-sintetica-amb-seu-a-barcelona-capta-una-inversio-de-dos-milions-deuros\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/invivo.partners\/ca\/2020\/04\/14\/nova-empresa-de-biologia-sintetica-amb-seu-a-barcelona-capta-una-inversio-de-dos-milions-deuros\/\"},\"author\":{\"name\":\"invivo\",\"@id\":\"https:\/\/invivo.partners\/#\/schema\/person\/f382d91fa1fbbe4bb94f3093438e5789\"},\"headline\":\"Nova empresa de biologia sint\u00e8tica amb seu a Barcelona capta una inversi\u00f3 de dos milions d\u2019euros\",\"datePublished\":\"2020-04-14T09:53:11+00:00\",\"dateModified\":\"2020-05-26T14:46:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/invivo.partners\/ca\/2020\/04\/14\/nova-empresa-de-biologia-sintetica-amb-seu-a-barcelona-capta-una-inversio-de-dos-milions-deuros\/\"},\"wordCount\":1040,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/invivo.partners\/#organization\"},\"keywords\":[\"Albert Ferrer\",\"Fondo Inversi\u00f3n\",\"inversi\u00f3n\",\"investment\",\"Invivo capital\",\"Invivo Ventures\",\"Llu\u00eds Pareras\",\"Luis Pareras\",\"Pulmobiotics\",\"Venture Capital\"],\"articleSection\":[\"Noticias\"],\"inLanguage\":\"ca\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/invivo.partners\/ca\/2020\/04\/14\/nova-empresa-de-biologia-sintetica-amb-seu-a-barcelona-capta-una-inversio-de-dos-milions-deuros\/\",\"url\":\"https:\/\/invivo.partners\/ca\/2020\/04\/14\/nova-empresa-de-biologia-sintetica-amb-seu-a-barcelona-capta-una-inversio-de-dos-milions-deuros\/\",\"name\":\"Nova empresa de biologia sint\u00e8tica amb seu a Barcelona capta una inversi\u00f3 de dos milions d\u2019euros - Invivo Partners\",\"isPartOf\":{\"@id\":\"https:\/\/invivo.partners\/#website\"},\"datePublished\":\"2020-04-14T09:53:11+00:00\",\"dateModified\":\"2020-05-26T14:46:38+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/invivo.partners\/ca\/2020\/04\/14\/nova-empresa-de-biologia-sintetica-amb-seu-a-barcelona-capta-una-inversio-de-dos-milions-deuros\/#breadcrumb\"},\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/invivo.partners\/ca\/2020\/04\/14\/nova-empresa-de-biologia-sintetica-amb-seu-a-barcelona-capta-una-inversio-de-dos-milions-deuros\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/invivo.partners\/ca\/2020\/04\/14\/nova-empresa-de-biologia-sintetica-amb-seu-a-barcelona-capta-una-inversio-de-dos-milions-deuros\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\/\/invivo.partners\/ca\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nova empresa de biologia sint\u00e8tica amb seu a Barcelona capta una inversi\u00f3 de dos milions d\u2019euros\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/invivo.partners\/#website\",\"url\":\"https:\/\/invivo.partners\/\",\"name\":\"Invivo Capital\",\"description\":\"Somos un fondo de capital riesgo especializado en proyectos early-stage del sector salud.\",\"publisher\":{\"@id\":\"https:\/\/invivo.partners\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/invivo.partners\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"ca\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/invivo.partners\/#organization\",\"name\":\"Invivo Capital\",\"url\":\"https:\/\/invivo.partners\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/invivo.partners\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg\",\"contentUrl\":\"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg\",\"width\":1200,\"height\":630,\"caption\":\"Invivo Capital\"},\"image\":{\"@id\":\"https:\/\/invivo.partners\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/invivo.partners\/#\/schema\/person\/f382d91fa1fbbe4bb94f3093438e5789\",\"name\":\"invivo\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/invivo.partners\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/3c1e935daee28cd9cccdda9f9bb7f784c23881fa1325206e7c53c9119500139c?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/3c1e935daee28cd9cccdda9f9bb7f784c23881fa1325206e7c53c9119500139c?s=96&d=mm&r=g\",\"caption\":\"invivo\"},\"url\":\"https:\/\/invivo.partners\/ca\/author\/invivocapital\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nova empresa de biologia sint\u00e8tica amb seu a Barcelona capta una inversi\u00f3 de dos milions d\u2019euros - Invivo Partners","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/invivo.partners\/ca\/2020\/04\/14\/nova-empresa-de-biologia-sintetica-amb-seu-a-barcelona-capta-una-inversio-de-dos-milions-deuros\/","og_locale":"ca_ES","og_type":"article","og_title":"Nova empresa de biologia sint\u00e8tica amb seu a Barcelona capta una inversi\u00f3 de dos milions d\u2019euros - Invivo Partners","og_description":"Luis Serrano i Maria Lluch, del Centre de Regulaci\u00f3 Gen\u00f2mica (CRG) a Barcelona, \u200b\u200bhan fundat Pulmobiotics S.L., una empresa precl\u00ednica que utilitza la biologia sint\u00e8tica per desenvolupar nous tractaments i vacunes per diversos tipus de malalties pulmonars. La companyia ha obtingut 2.000.000 d\u2019euros de capital inicial d\u2019una de les firmes biom\u00e8diques de capital risc l\u00edders","og_url":"https:\/\/invivo.partners\/ca\/2020\/04\/14\/nova-empresa-de-biologia-sintetica-amb-seu-a-barcelona-capta-una-inversio-de-dos-milions-deuros\/","og_site_name":"Invivo Partners","article_published_time":"2020-04-14T09:53:11+00:00","article_modified_time":"2020-05-26T14:46:38+00:00","author":"invivo","twitter_card":"summary_large_image","twitter_misc":{"Escrit per":"invivo","Temps estimat de lectura":"5 minuts"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/invivo.partners\/ca\/2020\/04\/14\/nova-empresa-de-biologia-sintetica-amb-seu-a-barcelona-capta-una-inversio-de-dos-milions-deuros\/#article","isPartOf":{"@id":"https:\/\/invivo.partners\/ca\/2020\/04\/14\/nova-empresa-de-biologia-sintetica-amb-seu-a-barcelona-capta-una-inversio-de-dos-milions-deuros\/"},"author":{"name":"invivo","@id":"https:\/\/invivo.partners\/#\/schema\/person\/f382d91fa1fbbe4bb94f3093438e5789"},"headline":"Nova empresa de biologia sint\u00e8tica amb seu a Barcelona capta una inversi\u00f3 de dos milions d\u2019euros","datePublished":"2020-04-14T09:53:11+00:00","dateModified":"2020-05-26T14:46:38+00:00","mainEntityOfPage":{"@id":"https:\/\/invivo.partners\/ca\/2020\/04\/14\/nova-empresa-de-biologia-sintetica-amb-seu-a-barcelona-capta-una-inversio-de-dos-milions-deuros\/"},"wordCount":1040,"commentCount":0,"publisher":{"@id":"https:\/\/invivo.partners\/#organization"},"keywords":["Albert Ferrer","Fondo Inversi\u00f3n","inversi\u00f3n","investment","Invivo capital","Invivo Ventures","Llu\u00eds Pareras","Luis Pareras","Pulmobiotics","Venture Capital"],"articleSection":["Noticias"],"inLanguage":"ca"},{"@type":"WebPage","@id":"https:\/\/invivo.partners\/ca\/2020\/04\/14\/nova-empresa-de-biologia-sintetica-amb-seu-a-barcelona-capta-una-inversio-de-dos-milions-deuros\/","url":"https:\/\/invivo.partners\/ca\/2020\/04\/14\/nova-empresa-de-biologia-sintetica-amb-seu-a-barcelona-capta-una-inversio-de-dos-milions-deuros\/","name":"Nova empresa de biologia sint\u00e8tica amb seu a Barcelona capta una inversi\u00f3 de dos milions d\u2019euros - Invivo Partners","isPartOf":{"@id":"https:\/\/invivo.partners\/#website"},"datePublished":"2020-04-14T09:53:11+00:00","dateModified":"2020-05-26T14:46:38+00:00","breadcrumb":{"@id":"https:\/\/invivo.partners\/ca\/2020\/04\/14\/nova-empresa-de-biologia-sintetica-amb-seu-a-barcelona-capta-una-inversio-de-dos-milions-deuros\/#breadcrumb"},"inLanguage":"ca","potentialAction":[{"@type":"ReadAction","target":["https:\/\/invivo.partners\/ca\/2020\/04\/14\/nova-empresa-de-biologia-sintetica-amb-seu-a-barcelona-capta-una-inversio-de-dos-milions-deuros\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/invivo.partners\/ca\/2020\/04\/14\/nova-empresa-de-biologia-sintetica-amb-seu-a-barcelona-capta-una-inversio-de-dos-milions-deuros\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/invivo.partners\/ca\/"},{"@type":"ListItem","position":2,"name":"Nova empresa de biologia sint\u00e8tica amb seu a Barcelona capta una inversi\u00f3 de dos milions d\u2019euros"}]},{"@type":"WebSite","@id":"https:\/\/invivo.partners\/#website","url":"https:\/\/invivo.partners\/","name":"Invivo Capital","description":"Somos un fondo de capital riesgo especializado en proyectos early-stage del sector salud.","publisher":{"@id":"https:\/\/invivo.partners\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/invivo.partners\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"ca"},{"@type":"Organization","@id":"https:\/\/invivo.partners\/#organization","name":"Invivo Capital","url":"https:\/\/invivo.partners\/","logo":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/invivo.partners\/#\/schema\/logo\/image\/","url":"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg","contentUrl":"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg","width":1200,"height":630,"caption":"Invivo Capital"},"image":{"@id":"https:\/\/invivo.partners\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/invivo.partners\/#\/schema\/person\/f382d91fa1fbbe4bb94f3093438e5789","name":"invivo","image":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/invivo.partners\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/3c1e935daee28cd9cccdda9f9bb7f784c23881fa1325206e7c53c9119500139c?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/3c1e935daee28cd9cccdda9f9bb7f784c23881fa1325206e7c53c9119500139c?s=96&d=mm&r=g","caption":"invivo"},"url":"https:\/\/invivo.partners\/ca\/author\/invivocapital\/"}]}},"_links":{"self":[{"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/posts\/1246","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/comments?post=1246"}],"version-history":[{"count":4,"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/posts\/1246\/revisions"}],"predecessor-version":[{"id":1259,"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/posts\/1246\/revisions\/1259"}],"wp:attachment":[{"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/media?parent=1246"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/categories?post=1246"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/tags?post=1246"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}